These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1310 related articles for article (PubMed ID: 19476406)

  • 21. The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.
    Baiza-Durán LM; Alvarez-Delgado J; Contreras-Rubio AY; Medrano-Palafox J; De Luca-Brown A; Casab-Rueda H; Cortés-Gastélum MA; Garcidueñas-Mejía MJ; Gómez-Bastar P; Gil-Carrasco F; Hartleben-Matkin C; Jiménez-Román J; Moreno-Marín ML; Paczka-Zapata JA; Velasco-Gallegos G; Vergara-Sinta M
    Ann Ophthalmol (Skokie); 2009; 41(3-4):174-8. PubMed ID: 20214051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components.
    Konstas AG; Katsimpris IE; Kaltsos K; Georgiadou I; Kordelou A; Nelson LA; Stewart WC
    Eye (Lond); 2008 Nov; 22(11):1391-7. PubMed ID: 17571086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
    Chiseliţă D; Antohi I; Medvichi R; Danielescu C
    Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
    Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diurnal intraocular pressure efficacy of the timolol-brimonidine fixed combination and the timolol-dorzolamide fixed combination as a first choice therapy in patients with pseudoexfoliation glaucoma.
    Yüksel N; Gök M; Altıntaş O; Cağlar Y
    Curr Eye Res; 2011 Sep; 36(9):804-8. PubMed ID: 21851166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.
    Martínez A; Sánchez M
    Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group.
    Adamsons IA; Polis A; Ostrov CS; Boyle JE
    J Glaucoma; 1998 Dec; 7(6):395-401. PubMed ID: 9871861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C; Oksüz H
    Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
    Konstas AG; Karabatsas CH; Lallos N; Georgiadis N; Kotsimpou A; Stewart JA; Stewart WC
    Ophthalmology; 2005 Apr; 112(4):603-8. PubMed ID: 15808251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
    J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
    Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment.
    Konstas AG; Kozobolis VP; Tsironi S; Makridaki I; Efremova R; Stewart WC
    Ophthalmology; 2008 Jan; 115(1):99-103. PubMed ID: 18166407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.
    Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L
    Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination.
    Akman A; Cetinkaya A; Akova YA; Ertan A
    Eye (Lond); 2005 Feb; 19(2):145-51. PubMed ID: 15184958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%.
    Konstas AG; Kozobolis VP; Lallos N; Christodoulakis E; Stewart JA; Stewart WC
    Eye (Lond); 2004 Dec; 18(12):1264-9. PubMed ID: 15218522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.